Jeil's TS-1 may shake whole cancer drug markets.
Published: 2004-02-03 06:57:00
Updated: 2004-02-03 06:57:00
Jeil Pharmaceutical Co. will introduce an attractive ant-cancer drug named TS-1 formulated with 3 components such as Tegaflu, Kimeracil and Oteracil under the technical licence with Japanese Taiho who originally developed it in 1997.
Compared to overall 25-30% of anti-cancer effectiveness with...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
